Benzinga
25 Sept 2025, 12:37 UTC · 52w ago
Verdict
Headline takes no side. We score QURE +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
UniQure soared 248% to a 5-year high after unveiling successful clinical trial results for its experimental Huntington's disease gene therapy.
More positive than 99% of claims this week
Stifel, Leerink, and Mizuho raised their price targets on QURE to $65, $68, and $60, respectively, with Mizuho calling the results 'game-changing.'
So whatMultiple major analysts significantly raising price targets overnight validates the clinical data and provides fundamental support for a sustained stock re-rating.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 99% of claims this week
If UniQure's gene therapy proves scalable and safe, its addressable market could run into billions, offering rare biotech upside.
So whatBillion-dollar addressable market potential underpins the long-term valuation ceiling, though realization is contingent on future execution and safety milestones.
More positive than 93% of claims this week
The durability of the rally depends on the longevity of patient outcomes in follow-up data and management's commercialization roadmap.
More negative than 91% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company's stock surged 248% following positive clinical trial results for a gene therapy, leading to multiple analyst price target upgrades.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
1h ago
−19.3%
Price is moving against the score
$38.32 vs $47.50 close before publication (Sep 24) · not market-adjusted
QURE chart →
